Rocacetrapib

DB15437InvestigationalSmall molecule

Rocacetrapib is under investigation in clinical trial NCT02156544 (Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519).

Mechanism: Pharmacologically active on Cholesteryl ester transfer protein
Curator reviewed
Formula / weight: C₃₁H₃₄F₇NO₃ · 601.606 g/mol (avg)
Code names: CKD-519

Resolves to

Compound

UNIIK9SP3L3YQPCAS1402796-27-3

Structure

InChIKeyGBHPDJQHZADVAA-SOKVYYICSA-NSMILESCOC1=C(C=C(C(C)C)C(F)=C1)C1=C(CN2[C@@H](C)[C@H](OC2=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)CC(C)(C)CC1

Targets

P11597CETP

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Rocacetrapib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account